# Pyridorin in Diabetic Nephropathy

Study · id `cardio:ct-nct02156843` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02156843](<https://clinicaltrials.gov/study/NCT02156843>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02156843

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 328 participants.

## Technical summary

Registry record NCT02156843. Randomized; quadruple masking; primary purpose treatment. Start 2014-06 (registry gives no type); primary completion 2017-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 328 participants (enrolled count; ClinicalTrials.gov record NCT02156843, source copy `cardio:ctgov-nct02156843-2016-03-09`, retrieved 2026-10-26)
- Start date: 2014-06 (registry gives no type) (ClinicalTrials.gov record NCT02156843, source copy `cardio:ctgov-nct02156843-2016-03-09`, retrieved 2026-10-26)
- Primary completion: 2017-12 (anticipated) (ClinicalTrials.gov record NCT02156843, source copy `cardio:ctgov-nct02156843-2016-03-09`, retrieved 2026-10-26)
- Completion: 2018-03 (anticipated) (ClinicalTrials.gov record NCT02156843, source copy `cardio:ctgov-nct02156843-2016-03-09`, retrieved 2026-10-26)
- Countries: United States; Australia; Bulgaria; France; Germany; Hong Kong SAR China; Hungary; Israel; Mauritius; Poland; Puerto Rico; Spain (ClinicalTrials.gov record NCT02156843, source copy `cardio:ctgov-nct02156843-2016-03-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02156843-2016-03-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Pyridorin in Diabetic Nephropathy
- Acronym: PIONEER
- Condition: Diabetic Nephropathy
- Condition: Diabetic Kidney Disease
- Intervention (Drug): Pyridorin
- Intervention (Drug): Placebo
- Lead sponsor: NephroGenex, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Collaborative Study Group (CSG)
- Collaborator class: NETWORK
- Collaborator: Medpace, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as a collaborator: Medpace, Inc. (`cardio:org-medpace-inc`)

## Provenance

Content hash: ec33d10985f583d914b3d71e4f770c17dd4718ad6d7951720c1b2eb5db3cadf3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
